Research Study

CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic Stroke) - a Randomised Clinical Trial of Low-dose Colchicine for Secondary Prevention After Stroke
Principal Investigator 
Thalia Field

Overview

Body Locations and Systems 
Stroke
ClinicalTrials.gov# 
NCT02898610
Status 
Recruiting
Study Start/End 
Aug 8, 2019 to Oct 31, 2021
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Karina Villaluna, Program Manager
Phone 
604-875-4554 ext.1
Purpose of Study 

The purpose of this study is to investigate the efficacy of low dose colchicine (0.5mg/day) plus usual care (defined as antiplatelet, lipid-lowering, antihypertensive treatment, and appropriate lifestyle advice) compared with usual care alone to prevent non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest, hospitalization for unstable angina and vascular death after ischaemic stroke or transient ischaemic attack (TIA) not caused by cardiac embolism or other defined causes unrelated to atherosclerosis.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.